Navigation Links
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

Small molecule drug inhibits key DNA repair mechanism involved in


DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced during an oral presentation at the American Society for Therapeutic Radiology and Oncology's (ASTRO) 49th Annual Meeting in Los Angeles that MP470, its clinical-stage multi-targeted tyrosine kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented here suggests that MP470 inhibits DNA damage repair through suppression of a critical DNA repair protein, Rad51. Dr. James Welsh of the University of Arizona, who conducted these pre-clinical studies, also revealed that the pre-clinical activity of MP470 against glioblastoma multiforme cells is synergistic with radiation.

Glioblastoma multiforme is often resistant to cytotoxic therapies and radiation, due to increased DNA repair and the inhibition of programmed cell death. Signaling pathways downstream of tyrosine kinases such as PDGFR and c- Met, are thought to be a key player in this resistance. Scientists at SuperGen found that MP470 inhibits these kinases and data presented today indicate that MP470 is active in inducing cell death in glioblastoma multiforme cell lines. Additionally, data suggest that MP470 induces sensitization to radiation through suppression of Rad51, indicating that it might not only inhibit tumor growth, but that it could also potentially enhance current therapies.

A copy of the poster presentation will be available in the pipeline section of SuperGen's Web site

"There is an urgent need for improved therapies for glioblastoma multiforme," said Dr. Greg Berk, Chief Medical Officer of SuperGen. "Our development strategy in areas of unmet need begins with this type of pre- clinical work that targets the biology of cancer and the weaknesses of current therapies. These studies support further clinical development of MP470 in glioblastoma multiforme."

MP470 is currently being evaluated in a phase 1 single agent clinical trial at two sites and will begin a phase 1b combination clinical trial with multiple chemotherapy regimens later this year.

About Glioblastoma Multiforme

Glioblastoma Multiforme the most common and aggressive malignant brain tumor in adults. Brain tumors are the second leading cause of cancer-related deaths in males ages 20-39 and the fifth leading cause of cancer-related deaths in women ages 20-39. Surgery is generally the first line of treatment, followed by radiation therapy and chemotherapy, either individually or in combination. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastoma multiforme almost always recur and survival rates remain low. Thus the disease remains a significant unmet clinical need in oncology.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.


Timothy L. Enns Mary M. Vegh

SuperGen, Inc. SuperGen, Inc.

SVP, Corporate Communications & Business Manager, Investor

Development Relations

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: E-mail:

SOURCE SuperGen Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Indian American Scientist at Work on Multi-targeted Drug
2. Phase 3 trials of two multi-kinase inhibitors against cancer
3. Enzyme Urokinase Better Option In Empyema For Kids
4. Blood pressure control with ACE inhibitor or diuretic?
5. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
6. Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression
7. Rejuvenation of Stem cells by GSK-3 Inhibitor
8. COX-2 inhibitors Lessen Breast Cancer Risk
9. LipB Protein Inhibitors Help To Fight Against TB
10. Birth Defects Link With ACE Inhibitor Use, FDA Reports
11. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop improving ... only fulfilling the needs of advisers and clients but going above and beyond ... top-tier customer service. However, there's always room for improvement, which is why the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, ... posters. This is one of Joplin's most famous and beautiful concert posters. The concert ... Michigan in Ann Arbor. The According to Hawley, "It is hard to believe that ...
(Date:11/26/2015)... ... 26, 2015 , ... Somu Sivaramakrishnan announced today that he ... now offers travelers, value and care based Travel Services, including exclusive pricing on ... as, cabin upgrades and special amenities such as, shore excursions, discounted fares, travel ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film Studios brings Final ... ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, ... giving users limitless opportunities to stylize and create designs quickly and easily, all ...
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ... is expected to boost the market growth, as 3D bioprinting ... --> 3D bioprinting market is expected to reach ... by Grand View Research Inc. Rising prevalence of chronic diseases ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology: